Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma (clinicaltrials.gov)

P1/2, N=33, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | Trial completion date: Jul 2027 --> Jan 2027

2 days ago

Enrollment closed • Trial completion date

doxorubicin hydrochloride • cyclophosphamide • vincristine • daunorubicin • Zynyz (retifanlimab-dlwr) • Rituxan Hycela (rituximab/hyaluronidase) • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq)

Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S. (PubMed, Anticancer Drugs)

The effect of GDF11 on chemotherapy sensitivity was investigated in HL60 cells treated with 10 μM daunorubicin (DNR)...In addition, CTSS activated the extracellular signal-regulated kinase 1 and 2 signaling pathway and inhibited endoplasmic reticulum stress in AML cells. In conclusion, GDF11 inhibited the growth and increased chemosensitivity through inhibiting CTSS expression in AML cells, providing potential therapeutic targets for AML treatment.

8 days ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CTSS (Cathepsin S) • CASP7 (Caspase 7)

daunorubicin

Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)

P2/3, N=450, Enrolling by invitation, First Affiliated Hospital of Zhejiang University

8 days ago

New P2/3 trial

azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin

Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy (clinicaltrials.gov)

P2/3, N=267, Enrolling by invitation, First Affiliated Hospital of Zhejiang University

8 days ago

New P2/3 trial

azacitidine • daunorubicin • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate) • aclarubicin

ARST1321: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (clinicaltrials.gov)

P2/3, N=140, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026

8 days ago

Trial completion • Trial completion date

doxorubicin hydrochloride • pazopanib • cyclophosphamide • ifosfamide • daunorubicin

Clinical profiling of AML1::ETO and KIT exon 17 mutation in pediatric AML by high-throughput drug sensitivity. (PubMed, BMC Cancer)

We conclude that KIT mutations, especially exon 17, confer a high-risk phenotype in otherwise favorable pediatric AML1::ETO AML. Our exploratory data suggest this may be associated with a chemoresistant profile, potentially driven by SOCS1-associated JAK-STAT dysregulation. These findings highlight the necessity of refined risk stratification based on KIT exon profiling and support targeting the SOCS1/JAK-STAT axis to overcome therapy resistance.

9 days ago

Journal

KIT (KIT proto-oncogene, receptor tyrosine kinase) • SOCS1 (Suppressor Of Cytokine Signaling 1)

KIT mutation

cytarabine • daunorubicin

Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia (clinicaltrials.gov)

P2, N=120, Recruiting, Chinese PLA General Hospital | Trial primary completion date: Dec 2027 --> Sep 2027

9 days ago

Trial primary completion date

Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • daunorubicin • aclarubicin

14d

ETCTN 10596: A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease (clinicaltrials.gov)

P1, N=38, Recruiting, National Cancer Institute (NCI) | N=28 --> 38

14 days ago

Enrollment change

FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • CD33 (CD33 Molecule)

FLT3-ITD mutation • FLT3 mutation • NPM1 mutation

daunorubicin • Revuforj (revumenib) • Starasid (cytarabine ocfosfate)

15d

Lnc-BRMS1L-4 and ZEB1-AS1 expression in acute lymphoblastic leukemia and its correlation with acute graft-versus-host disease after hematopoietic stem cell transplantation. (PubMed, Transplant Cell Ther)

All patients received standard chemotherapy, consisting of daunorubicin...ZEB1-AS1 levels were also higher in patients with COVID-19 positive than in those without, which may indicate a connection between viral infection and the molecular pathways involving this oncogenic lncRNA. These findings highlight the importance of ZEB1-AS1 in the pathogenesis of ALL and suggest their roles in disease characterization and possibly in therapeutic targeting.

15 days ago

Journal

ZEB1 (Zinc Finger E-box Binding Homeobox 1)

daunorubicin